|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song HJ, Qiu ZL, Shen CT, Wei WJ and Luo
QY: Pulmonary metastases in differentiated thyroid cancer: Efficacy
of radioiodine therapy and prognostic factors. Eur J Endocrinol.
173:399–408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Durante C, Haddy N, Baudin E, Leboulleux
S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De
Vathaire F, et al: Long-term outcome of 444 patients with distant
metastases from papillary and follicular thyroid carcinoma:
Benefits and limits of radioiodine therapy. J Clin Endocrinol
Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xing M, Haugen BR and Schlumberger M:
Progress in molecular-based management of differentiated thyroid
cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang W, Kang H, Zhao Y, Min I, Wyrwas B,
Moore M, Teng L, Zarnegar R, Jiang X and Fahey TJ III: Targeting
autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J
Clin Endocrinol Metab. 102:634–643. 2017.PubMed/NCBI
|
|
7
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Adnane L, Trail PA, Taylor I and Wilhelm
SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that
targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases
VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brose MS, Nutting CM, Jarzab B, Elisei R,
Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R,
Shong YK, et al DECISION investigators, : Sorafenib in radioactive
iodine-refractory, locally advanced or metastatic differentiated
thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet.
384:319–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pitoia F and Jerkovich F: Selective use of
sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther.
10:1119–1131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yi H, Long B, Ye X, Zhang L, Liu X and
Zhang C: Autophagy: A potential target for thyroid cancer therapy
(Review). Mol Clin Oncol. 2:661–665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heqing Y, Bin L, Xuemei Y and Linfa L: The
role and mechanism of autophagy in sorafenib targeted cancer
therapy. Crit Rev Oncol Hematol. 100:137–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prieto-Domínguez N, Ordóñez R, Fernández
A, García-Palomo A, Muntané J, González-Gallego J and Mauriz JL:
Modulation of autophagy by sorafenib: Effects on treatment
response. Front Pharmacol. 7:1512016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke
AW, Wang XY, Dai Z, Peng YF, Gu CY, et al: Targeting autophagy
enhances sorafenib lethality for hepatocellular carcinoma via ER
stress-related apoptosis. Autophagy. 7:1159–1172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimizu S, Takehara T, Hikita H, Kodama T,
Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, et
al: Inhibition of autophagy potentiates the antitumor effect of the
multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J
Cancer. 131:548–557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan H, Li AJ, Ma SL, Cui LJ, Wu B, Yin L
and Wu MC: Inhibition of autophagy significantly enhances
combination therapy with sorafenib and HDAC inhibitors for human
hepatoma cells. World J Gastroenterol. 20:4953–4962. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu
B, Pan S, Dong X, Tan G, Wei Z, et al: Inhibition of Akt reverses
the acquired resistance to sorafenib by switching protective
autophagy to autophagic cell death in hepatocellular carcinoma. Mol
Cancer Ther. 13:1589–1598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu L, McPhee CK, Zheng L, Mardones GA,
Rong Y, Peng J, Mi N, Zhao Y, Liu Z, Wan F, et al: Termination of
autophagy and reformation of lysosomes regulated by mTOR. Nature.
465:942–946. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zou Y, Ling YH, Sironi J, Schwartz EL,
Perez-Soler R and Piperdi B: The autophagy inhibitor chloroquine
overcomes the innate resistance of wild-type EGFR non-small-cell
lung cancer cells to erlotinib. J Thorac Oncol. 8:693–702. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang C, Hu Q and Shen H-M: Pharmacological
inhibitors of autophagy as novel cancer therapeutic agents.
Pharmacol Res. 105:164–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salvesen GS: Caspases: Opening the boxes
and interpreting the arrows. Cell Death Differ. 9:3–5. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghavami S, Hashemi M, Ande SR, Yeganeh B,
Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, et
al: Apoptosis and cancer: Mutations within caspase genes. J Med
Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Günther A, Luczak V, Abel T and Baumann A:
Caspase-3 and GFAP as early markers for apoptosis and astrogliosis
in shRNA-induced hippocampal cytotoxicity. J Exp Biol.
220:1400–1404. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhong Y, Wang QJ, Li X, Yan Y, Backer JM,
Chait BT, Heintz N and Yue Z: Distinct regulation of autophagic
activity by Atg14L and Rubicon associated with Beclin
1-phosphatidylinositol-3-kinase complex. Nat Cell Biol. 11:468–476.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vlahakis A and Powers T: A role for TOR
complex 2 signaling in promoting autophagy. Autophagy.
10:2085–2086. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Díaz-Troya S, Pérez-Pérez ME, Florencio FJ
and Crespo JL: The role of TOR in autophagy regulation from yeast
to plants and mammals. Autophagy. 4:851–865. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yi H, Ye X, Long B, Ye T, Zhang L, Yan F,
Yang Y and Li L: Inhibition of the AKT/mTOR pathway augments the
anticancer effects of sorafenib in thyroid cancer. Cancer Biother
Radiopharm. 32:176–183. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Valerio L, Pieruzzi L, Giani C, Agate L,
Bottici V, Lorusso L, Cappagli V, Puleo L, Matrone A, Viola D, et
al: Targeted therapy in thyroid cancer: State of the art. Clin
Oncol (R Coll Radiol). 29:316–324. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bruix J, Takayama T, Mazzaferro V, Chau
GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, et al STORM
investigators, : Adjuvant sorafenib for hepatocellular carcinoma
after resection or ablation (STORM): A phase 3, randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 16:1344–1354.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tarlock K, Chang B, Cooper T, Gross T,
Gupta S, Neudorf S, Adlard K, Ho PA, McGoldrick S, Watt T, et al:
Sorafenib treatment following hematopoietic stem cell transplant in
pediatric FLT3/ITD acute myeloid leukemia. Pediatr Blood Cancer.
62:1048–1054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hutson TE, Escudier B, Esteban E,
Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR,
Hariharan S, et al: Randomized phase III trial of temsirolimus
versus sorafenib as second-line therapy after sunitinib in patients
with metastatic renal cell carcinoma. J Clin Oncol. 32:760–767.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Beardsley EK, Hotte SJ, North S, Ellard
SL, Winquist E, Kollmannsberger C, Mukherjee SD and Chi KN: A phase
II study of sorafenib in combination with bicalutamide in patients
with chemotherapy-naive castration resistant prostate cancer.
Invest New Drugs. 30:1652–1659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY,
Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, et al Investigators'
Study Group, : Safety and efficacy of tigatuzumab plus sorafenib as
first-line therapy in subjects with advanced hepatocellular
carcinoma: A phase 2 randomized study. J Hepatol. 63:896–904. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu L, Wang H, Huang L, Zhao Y and Wang J:
Crosstalk between autophagy and intracellular radiation response
(Review). Int J Oncol. 49:2217–2226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang B, Liu X, Liu Y, Kong D, Liu X,
Zhong R and Ma S: Inhibition of autophagy sensitizes MDR-phenotype
ovarian cancer SKVCR cells to chemotherapy. Biomed Pharmacother.
82:98–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thorburn A, Thamm DH and Gustafson DL:
Autophagy and cancer therapy. Mol Pharmacol. 85:830–838. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
White E: The role for autophagy in cancer.
J Clin Invest. 125:42–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
O'Neill PM, Bray PG, Hawley SR, Ward SA
and Park BK: 4-Aminoquinolines-past, present, and future: A
chemical perspective. Pharmacol Ther. 77:29–58. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yin Z, Pascual C and Klionsky DJ:
Autophagy: Machinery and regulation. Microb Cell. 3:588–596. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Grimaldi A, Santini D, Zappavigna S,
Lombardi A, Misso G, Boccellino M, Desiderio V, Vitiello PP, Di
Lorenzo G, Zoccoli A, et al: Antagonistic effects of chloroquine on
autophagy occurrence potentiate the anticancer effects of
everolimus on renal cancer cells. Cancer Biol Ther. 16:567–579.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zinn RL, Gardner EE, Dobromilskaya I,
Murphy S, Marchionni L, Hann CL and Rudin CM: Combination treatment
with ABT-737 and chloroquine in preclinical models of small cell
lung cancer. Mol Cancer. 12:162013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
King MA, Ganley IG and Flemington V:
Inhibition of cholesterol metabolism underlies synergy between mTOR
pathway inhibition and chloroquine in bladder cancer cells.
Oncogene. 35:4518–4528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Maes H, Kuchnio A, Peric A, Moens S, Nys
K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, et
al: Tumor vessel normalization by chloroquine independent of
autophagy. Cancer Cell. 26:190–206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen X, Clark J, Wunderlich M, Fan C,
Davis A, Chen S, Guan JL, Mulloy JC, Kumar A and Zheng Y: Autophagy
is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and
anti-leukemic effect of chloroquine. Autophagy. 13:955–966. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH,
Chen PJ and Cheng AL: Activation of phosphatidylinositol
3-kinase/Akt signaling pathway mediates acquired resistance to
sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther.
337:155–161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Carlo-Stella C, Locatelli SL, Giacomini A,
Cleris L, Saba E, Righi M, Guidetti A and Gianni AM: Sorafenib
inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways
in tumor and vascular cells. PLoS One. 8:e616032013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu G, Yuan Y, Long M, Luo T, Bian J, Liu
X, Gu J, Zou H, Song R, Wang Y, et al: Beclin-1-mediated autophagy
protects against cadmium-activated apoptosis via the Fas/FasL
pathway in primary rat proximal tubular cell culture. Sci Rep.
7:9772017. View Article : Google Scholar : PubMed/NCBI
|
